RespireRx Pharmaceuticals Inc (fka RSPI)

[atheroprevent]

http://www3.interscience.wiley.com/journal/76508397/abstract?CRETRY=1&SRETRY=0

I have not used it but it would make sense to test this to assess response to therapy in Parkinsons.

Interesting pitfalls are staring to emerge in the use of biomarkers.

Ldl cholesterol poorly predicts risk in individuals, while remaining robust for populations.

Hgba1c long thought to predict favorable diabetes outcome in all landmark studies, is now shown to be associated with increased risk in some circumstances with aggressive therapy.